Breast cancer and prostaglandins: a new approach to treatment.
The effect of the non-steroidal inhibitor of prostaglandin synthesis, flurbiprofen, has been studied on a transplanted mouse mammary tumour of spontaneous origin. Daily administration of 2.5 mg/kg flurbiprofen signficantly reduced the growth of this NC adenocarcinoma transplanted subcutaneously into the right flank of WHT/Ht mice. Histological examination showed that primary tumours excised at 3 weeks from treated mice tended to have a more prominent lymphocytic infiltration. There was a non-significant tendency for mice treated with flurbiprofen alone to survive longer after tumour excision and to develop less local metastases, although scar recurrences seemed unaffected. The effect of adjuvant chemotherapy and local radiotherapy on local metastases and survival time tended to be greater when flurbiprofen was also given. This work supports and extends the basis for prospective clinical trials to evaluate the role of prostaglandins in human cancer and the value of prostaglandin synthesis inhibitors in cancer therapy.
D000818:Animals; D005260:Female; D005480:Flurbiprofen / Q000627:therapeutic use*; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy* / Q000401:mortality / Q000628:therapy; D051379:Mice; D009364:Neoplasm Recurrence, Local / Q000628:therapy; D009368:Neoplasm Transplantation; D011422:Propionates / Q000627:therapeutic use*; D011448:Prostaglandin Antagonists / Q000627:therapeutic use*
D011422:Propionates; D011448:Prostaglandin Antagonists; D005480:Flurbiprofen